We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+18.21%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$9.8B
AUM Growth
+$1.86B
Cap. Flow
-$1.4B
Cap. Flow %
-14.24%
Top 10 Hldgs %
73.27%
Holding
123
New
14
Increased
15
Reduced
12
Closed
2

Top Buys

Rank Stock Value
1
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$247M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$188M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$112M
4
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$91.9M
5
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$75.9M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$67.4M
2
XOMA
Xoma
XOMA
+$26.3M
3
AMBI
Ambit Biosciences Corp
AMBI
+$16.8M
4
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$14.3M
5
RPRX
Repros Therapeutics Inc.
RPRX
+$6.64M

Sector Composition

Rank Sector Weight
1 Healthcare 42.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLRN
101
DELISTED
Acceleron Pharma
XLRN
$1.12M 0.01%
28,765
– –
RIGL icon
102
Rigel Pharmaceuticals
RIGL
$731M
$1.09M 0.01%
48,197
– –
ARCT icon
103
Arcturus Therapeutics
ARCT
$162M
$1.08M 0.01%
+41,410
New +$1.32M
TCRT icon
104
Alaunos Therapeutics
TCRT
$4.69M
$982K 0.01%
1,291
-340
-21% -$180K
FPRX
105
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$535K 0.01%
19,823
– –
QURE icon
106
uniQure
QURE
$2.78B
$454K ﹤0.01%
30,672
– –
CCXI
107
DELISTED
ChemoCentryx, Inc.
CCXI
$342K ﹤0.01%
50,000
– –
AST
108
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
$54K ﹤0.01%
+16,775
New +$67.5K
BTX.WS
109
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
$22K ﹤0.01%
+20,525
New +$22.2K
AVNR
110
CALL
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
– –
-9,356,200
Closed -$112M
AMBI
111
DELISTED
Ambit Biosciences Corp
AMBI
– –
-1,093,332
Closed -$16.8M
1 2 3 4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2014 Portfolio in Review

As of Q4 2014, Baker Bros. Advisors held 123 positions worth $9.8B, up 23% from $7.94B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Baker Bros. Advisors withdrew a net $1.4B in Q4 2014, closing 2 positions and reducing 12 holdings. Its most notable exit was Ambit Biosciences Corp, an estimated $16.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 39% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in Bellicum Pharmaceuticals, Inc. worth $98.7M.

  • Baker Bros. Advisors's largest Q4 2014 buy was Bellicum Pharmaceuticals, Inc.: 428,373 shares worth $98.7M.
  • Baker Bros. Advisors added most to AVANIR PHARMACEUTICALS, INC CL A in Q4 2014, an estimated $247M increase.
  • Baker Bros. Advisors's biggest Q4 2014 reduction was PHARMACYCLICS INC, cutting an estimated $67.4M.
  • Baker Bros. Advisors fully exited Ambit Biosciences Corp in Q4 2014, selling an estimated $16.8M.
  • Baker Bros. Advisors's ten largest holdings make up 73% of its $9.8B portfolio in Q4 2014.
  • Baker Bros. Advisors opened 14 new positions and closed 2 in Q4 2014.
  • Baker Bros. Advisors's portfolio value rose 23% quarter-over-quarter to $9.8B.

Based on Baker Bros. Advisors's 13F filing for Q4 2014, filed 17 Feb 2015.